Stock Track | Tarsus Pharmaceuticals Soars 10.64% Intraday on Positive Analyst Ratings and Price Target Increases

Stock Track

Feb 24

Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 10.64% during intraday trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.

The surge follows positive analyst attention from multiple financial institutions. H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Tarsus Pharmaceuticals with a price target of $88.00, citing a sustained growth outlook driven by XDEMVY's rapid ramp and the expanding lotilaner pipeline.

Additionally, BofA raised its price target on Tarsus Pharmaceuticals to $90 from $88 while maintaining a Buy rating on the shares, following a revenue beat in the company's recent quarterly results. These analyst actions reflect growing confidence in the company's growth prospects and financial performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1130927940"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130927940\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130927940?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130927940","market":"hk","top_or_hot":-1,"title":"Stock Track | Tarsus Pharmaceuticals Soars 10.64% Intraday on Positive Analyst Ratings and Price Target Increases","media":"Stock Track","content":"<p>Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 10.64% during intraday trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.</p><p>The surge follows positive analyst attention from multiple financial institutions. H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Tarsus Pharmaceuticals with a price target of $88.00, citing a sustained growth outlook driven by XDEMVY's rapid ramp and the expanding lotilaner pipeline.</p><p>Additionally, BofA raised its price target on Tarsus Pharmaceuticals to $90 from $88 while maintaining a Buy rating on the shares, following a revenue beat in the company's recent quarterly results. These analyst actions reflect growing confidence in the company's growth prospects and financial performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tarsus Pharmaceuticals Soars 10.64% Intraday on Positive Analyst Ratings and Price Target Increases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tarsus Pharmaceuticals Soars 10.64% Intraday on Positive Analyst Ratings and Price Target Increases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 10.64% during intraday trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.</p><p>The surge follows positive analyst attention from multiple financial institutions. H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Tarsus Pharmaceuticals with a price target of $88.00, citing a sustained growth outlook driven by XDEMVY's rapid ramp and the expanding lotilaner pipeline.</p><p>Additionally, BofA raised its price target on Tarsus Pharmaceuticals to $90 from $88 while maintaining a Buy rating on the shares, following a revenue beat in the company's recent quarterly results. These analyst actions reflect growing confidence in the company's growth prospects and financial performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TARS","symbol_name":"Tarsus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1130927940","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130927940","pubTimestamp":1771944215,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 10.64% during intraday trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.The surge follows...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TARS":"Tarsus Pharmaceuticals, Inc."},"translate_title":"个股追踪|分析师正面评级及目标价上调Tarsus Pharmaceuticals盘中大涨10.64%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1},"content_text":"Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 10.64% during intraday trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.The surge follows positive analyst attention from multiple financial institutions. H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Tarsus Pharmaceuticals with a price target of $88.00, citing a sustained growth outlook driven by XDEMVY's rapid ramp and the expanding lotilaner pipeline.Additionally, BofA raised its price target on Tarsus Pharmaceuticals to $90 from $88 while maintaining a Buy rating on the shares, following a revenue beat in the company's recent quarterly results. These analyst actions reflect growing confidence in the company's growth prospects and financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}